Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover Study

Published:2020-06-28 Issue:7 Volume:40 Page:623-631
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Chen Gang¹,Zhang Dan¹,Du Aihua¹,Zhang Yanan¹,Zhang Ying¹,Zhang Lina¹,Zang Siqi¹,Liu Xiaona¹,Wang Zejuan¹,Zhen Haiqing²,Liu Yujing³,Yang Shuya⁴,Wang Jin¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology Aerospace Center Hospital Beijing China

2. GCP Office Aerospace Center Hospital Beijing China

3. Beijing Sun‐Novo Pharmaceutical Research Co., Ltd. Beijing China

4. President’s Office Aerospace 731 Hospital Beijing China

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2432

Reference23 articles.

1. International Diabetes Federation (IDF).IDF Diabetes Atlas 9th Edition 2019. Available fromhttps://diabetesatlas.org/en/. Accessed February 28 2020.

2. Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2013 Edition);Chinese Diabetes Society (CDS);Chin J Front Med Sci,2015

3. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

4. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

5. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions;Pharmaceuticals;2022-02-03